Carnegie Capital Asset Management LLC lifted its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Get Rating) by 6.0% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 17,734 shares of the company’s stock after buying an additional 997 shares during the quarter. Carnegie Capital Asset Management LLC’s holdings in AstraZeneca were worth $1,062,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors also recently modified their holdings of the company. Allworth Financial LP lifted its holdings in shares of AstraZeneca by 23.8% in the 2nd quarter. Allworth Financial LP now owns 3,616 shares of the company’s stock worth $239,000 after purchasing an additional 695 shares in the last quarter. Cambridge Investment Research Advisors Inc. lifted its holdings in shares of AstraZeneca by 3.4% in the 2nd quarter. Cambridge Investment Research Advisors Inc. now owns 90,055 shares of the company’s stock worth $5,950,000 after purchasing an additional 2,998 shares in the last quarter. First Affirmative Financial Network bought a new position in shares of AstraZeneca in the 2nd quarter worth $203,000. Archford Capital Strategies LLC bought a new position in shares of AstraZeneca in the 2nd quarter worth $539,000. Finally, Transcend Capital Advisors LLC lifted its holdings in shares of AstraZeneca by 3.7% in the 2nd quarter. Transcend Capital Advisors LLC now owns 5,648 shares of the company’s stock worth $373,000 after purchasing an additional 203 shares in the last quarter. 21.55% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several equities analysts have weighed in on the company. UBS Group cut AstraZeneca from a “buy” rating to a “neutral” rating in a research note on Tuesday, June 14th. StockNews.com upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research note on Monday, July 11th. Citigroup raised their target price on AstraZeneca from £105 ($126.87) to £130 ($157.08) in a research report on Tuesday, July 12th. AlphaValue raised AstraZeneca to a “reduce” rating in a research report on Monday, August 22nd. Finally, TheStreet lowered AstraZeneca from a “b-” rating to a “c” rating in a report on Tuesday, August 30th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $8,840.50.
AstraZeneca Price Performance
AstraZeneca Cuts Dividend
The company also recently declared a semi-annual dividend, which was paid on Monday, September 12th. Investors of record on Friday, August 12th were paid a $0.465 dividend. The ex-dividend date was Thursday, August 11th. This represents a yield of 2.2%. AstraZeneca’s payout ratio is -221.95%.
AstraZeneca Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.
- Get a free copy of the StockNews.com research report on AstraZeneca (AZN)
- What Steelcase’s Earnings Say About the Return to the Office?
- The Institutions Hold On To Darden Restaurants International
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.